Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.
Elizabeth M. Swisher, MD
Advertisement
Articles by Elizabeth M. Swisher, MD
Elizabeth M. Swisher, MD, discusses the implications of the phase III VELIA/GOG-3005 trial in ovarian cancer.
Elizabeth M. Swisher, MD, discusses how the phase III VELIA/GOG-3005 trial compares with other trials examining up-front maintenance therapy in ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Swisher on the Limitations of HRD as a Biomarker in Ovarian CancerPublished: April 23rd 2020 | Updated:
Dr. Swisher on How the VELIA Trial Stands Out in Ovarian Cancer ResearchPublished: April 2nd 2020 | Updated:
Dr. Swisher on the Implications of the VELIA Trial in Ovarian CancerPublished: April 10th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5